267 results on '"Goll, G."'
Search Results
52. Transition to gapless superconductivity in YBa2(Cu1−x Zn x )3O7
53. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial
54. Magnetic phase diagram of PrPb3 investigated by specific heat and magnetocaloric effect
55. Low-temperature specific heat of the cluster compound Au55(P(C6H5)3)12Cl6
56. Low-temperature specific heat of the cluster compound Au55 (P(C6H5)3)12Cl6
57. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care
58. SAT0185 Certolizumab pegol serum levels ≥20 mg/l are associated with improvement in das28 in rheumatoid arthritis patients. data from the nor-dmard study
59. FRI0645 Anti-drug antibodies to certolizumab pegol are associated with low drug levels and reduced clinical response at 3 months in patients with inflammatory joint diseases. data from the nor-dmard study.
60. FRI0663 The fine specificity of anti-drug antibody responses to originator and biosimilar infliximab: analyses across five diseases from the 52-week randomized nor-switch study
61. P483 Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: Explorative subgroup analyses in IBD from the NOR-SWITCH EXTENSION trial
62. Point-contact spectroscopy on the heavy-fermion superconductor UPt 3 in the normal and superconducting states
63. Point-contact spectroscopy on the La-doped Kondo insulator Ce 3Bi 4Pt 3
64. Low-energy excitations in CeBiPt
65. Temperature dependence of the irreversibility field of Ba1−xKxBiO3
66. ADALIMUMAB SERUM DRUG LEVELS AND ANTIDRUG ANTIBODIES: ASSOCIATION TO DISEASE ACTIVITY AND DRUG SURVIVAL IN INFLAMMATORY ARTHRITIS PATIENTS.
67. DIFFERENCES IN SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS TREATED WITH ORIGINATOR VS BIOSIMILAR ADALIMUMAB.
68. INCIDENCE AND CLINICAL OUTCOME OF COVID-19 RELATED TO POST-VACCINATION ANTIBODY LEVELS IN PATIENTS ON IMMUNOSUPPRESSIVE THERAPY: A PROSPECTIVE STUDY IN THE OMICRON ERA.
69. Non-medical switch from originator to biosimilar in fliximab in patients with inflammatory arthritis:impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry
70. Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease:Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry
71. THU0123 Non-Medical Switch from Originator To Biosimilar Infliximab among Patients with Inflammatory Rheumatic Disease – Impact on S-Infliximab and Antidrug-Antibodies. Results from The National Danish Rheumatologic Biobank and The Danbio Registry
72. Investigation of Sr2RuO4–Pt contacts in an applied magnetic field
73. Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.
74. Possible magnetic-field-induced Lifshitz transition in Ce1−xLaxBiPt
75. Fermi surfaces of the half-Heusler compounds Ce1-xLaxBiPt
76. Die pathologische Fraktur
77. Magnetic-field- and temperature-dependent Fermi surface of CeBiPt
78. Fermi surfaces of the half heusler compounds Ce1-xLaxBiPt
79. Fermi Surface of the Half Heusler Compounds Ce1−xLaxBiPt
80. SAFETY OF BIVALENT SARS-COV-2 VACCINES AS A SECOND BOOSTER DOSE IN ARTHRITIS PATIENTS ON IMMUNOSUPPRESSIVE THERAPIES.
81. CLINICAL CONSEQUENCES OF INFLIXIMAB IMMUNOGENICITY AND THE IMPACT OF THERAPEUTIC DRUG MONITORING: SECONDARY ANALYSES OF A RANDOMISED CLINICAL TRIAL.
82. Transport properties of CeBiPt in magnetic fields up to 60 T
83. Approaching quantum criticality in a partially geometrically frustrated heavy-fermion metal
84. Probing superconductivity in Sr 2RuO 4 by point-contact spectroscopy
85. Spin-triplet superconductivity in Sr2RuO4 probed by Andreev reflection
86. Second superconducting energy gap of Nb3Sn observed by breakjunction point-contact spectroscopy
87. Andreev experiments on superconductor/ferromagnet point contacts
88. Observation of a second energy gap in Nb3Sn point contacts
89. Experimental verification of contact-size estimates in point-contact spectroscopy on superconductor/ferromagnet heterocontacts
90. Point-contact spectroscopy in heavy-fermion superconductors
91. Second superconducting energy gap ofNb3Snobserved by breakjunction point-contact spectroscopy
92. A scanning tunneling microscope for a dilution refrigerator
93. Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs
94. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study
95. Magneto-optical spectra of Mn-Ge films
96. Size Dependence of Current Spin Polarization through Superconductor/Ferromagnet Nanocontacts
97. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study
98. Magnetic-field- and temperature-dependent Fermi surface of CeBiPt
99. Observation of a Second Energy Gap in Nb3Sn Point Contacts
100. Magnetic-Field-Induced Band-Structure Change in CeBiPt
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.